Validation of the eighth edition American Joint Committee on Cancer staging system for human papillomavirus-associated oropharyngeal cancer

Head & Neck ◽  
2017 ◽  
Vol 40 (3) ◽  
pp. 457-466 ◽  
Author(s):  
John D. Cramer ◽  
Kate E. Hicks ◽  
Alfred W. Rademaker ◽  
Urjeet A. Patel ◽  
Sandeep Samant
Keyword(s):  
Human Papillomavirus ◽  
Oropharyngeal Cancer ◽  
Staging System ◽  
Cancer Staging ◽  
American Joint Committee ◽  
Eighth Edition

Application of the Eighth Edition American Joint Committee on Cancer Staging System for HPV-Related Oropharyngeal Cancer Treated With Transoral Robotic Surgery

2017 ◽  
Vol 128 (5) ◽  
pp. 1133-1139 ◽  
Author(s):  
Arvind K. Badhey ◽  
Ashley Olson ◽  
Sameep Kadakia ◽  
Jack Russo ◽  
Peter Ting ◽  
...  
Keyword(s):  
Robotic Surgery ◽  
Oropharyngeal Cancer ◽  
Staging System ◽  
Cancer Staging ◽  
Transoral Robotic Surgery ◽  
American Joint Committee ◽  
Eighth Edition

scholarly journals Survival of patients with early invasive melanoma down-staged under the new eighth edition of the American Joint Committee on Cancer staging system

2019 ◽  
Vol 80 (1) ◽  
pp. 272-274 ◽  
Author(s):  
Lena A. von Schuckmann ◽  
Maria Celia B. Hughes ◽  
Rebecca Lee ◽  
Paul Lorigan ◽  
Kiarash Khosrotehrani ◽  
...  
Keyword(s):  
Staging System ◽  
Cancer Staging ◽  
American Joint Committee ◽  
Eighth Edition

scholarly journals Value of transoral surgery for human papillomavirus-mediated oropharyngeal cancer: validation of a new staging system in Japanese patients

2019 ◽  
Vol 47 (10) ◽  
pp. 5048-5059 ◽  
Author(s):  
Eiko Kimura ◽  
Koji Araki ◽  
Masayuki Tomifuji ◽  
Yuya Tanaka ◽  
Kosuke Uno ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Oropharyngeal Cancer ◽  
Poor Prognosis ◽  
Staging System ◽  
Japanese Patients ◽  
Clinical Staging ◽  
Transoral Surgery ◽  
Seventh Edition ◽  
Eighth Edition ◽  
Ajcc Staging

Objective This study aimed to validate new staging of Japanese patients with human papillomavirus-mediated oropharyngeal cancer (HPV+-OPC) and the effectiveness of transoral surgery. Methods Fifty-three patients with HPV+-OPC were classified according to the seventh and eighth editions of the American Joint Committee on Cancer (AJCC) staging, along with assessment of prognosis, smoking and alcohol status, and treatment outcome. Transoral videolaryngoscopic surgery (TOVS) was performed as transoral surgery. Results The 5-year overall survival (OS) rate was 77.3% in all patients. Five-year OS rates of seventh edition staging were as follows: II, 100%; III, 100%; IVa, 75.9%; and IVb and IVc, 0%. Five-year OS rates of the eighth edition clinical staging were as follows: I, 89.3%; II, 88.9%; III, 46.3%; and IV, 0%. In non-smoking and smoking patients with HPV+-OPC, the 5-year OS rates were 90.9% and 70.7%, respectively. TOVS was used for treating 20 smokers with HPV+-OPC (5-year OS: 85.7%), while 12 were treated with chemoradiotherapy (5-year OS: 75.0%). Conclusions The eighth edition of the AJCC determines the prognosis of HPV+-OPC more accurately than the seventh edition in clinical staging. Smokers with HPV+-OPC have a poor prognosis, but TOVS might improve the prognosis.

Prognostic Significance of Smoking in Human Papillomavirus– Positive Oropharyngeal Cancer Under American Joint Committee on Cancer Eighth Edition Stage

2020 ◽  
Vol 130 (8) ◽  
pp. 1961-1966
Author(s):  
Smrithi Chidambaram ◽  
Erik R. Nakken ◽  
William Kennedy ◽  
Wade L. Thorstad ◽  
Stephanie Y. Chen ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Oropharyngeal Cancer ◽  
Prognostic Significance ◽  
American Joint Committee ◽  
Eighth Edition

scholarly journals Clinical and prognostic impact of changes in the tnm system of the american joint committee for cancer, eighth edition, in patients with breast cancer

Mastology ◽  
2020 ◽  
Vol 30 (Suppl 1) ◽  
Author(s):  
Cynthia Mara Brito Lins Pereira ◽  
Yasmin de Farias Khayat ◽  
Mariana Rocha Bohone
Keyword(s):  
Breast Cancer ◽  
Staging System ◽  
Cancer Staging ◽  
Tnm Staging ◽  
Prognostic Impact ◽  
Tnm System ◽  
American Joint Committee ◽  
Therapeutic Decisions ◽  
Eighth Edition ◽  
The Impact

In Brazil, breast cancer is the first among the most prevalent malignancies in women, without considering non-melanoma skin cancer. However, in spite of the high number of deaths caused by breast cancer, there has been a great reduction in mortality rates and greater survival of patients with metastatic disease in the last decades. Such improvements are related to advances in treatment and greater knowledge about the biology of breast cancer. The American Joint Committee for Cancer (AJCC) cancer staging system is one of the important tools for doctors, and helps to predict disease progression and make therapeutic decisions. Therapeutic planning and prognosis of patients is possible through staging. Since the publication of the first edition of the Cancer Staging Manual, AJCC has insisted on seeing anatomical information. TNM staging (T: tumor; N: lymph nodes; M: metastasis). Limitations regarding this staging method were evidenced, as it is based only on anatomy and does not take biological factors into account. Through immunohistochemical study, breast cancer is subdivided into different molecular subtypes. When considering the modifications of the new edition of the TNM/AJCC system with respect to the prognostic and predictive factors of cancer, there may be a reclassification of patients, leading to a more reliable approach to their real disease condition. Objective: To analyze the impact generated by the update of the TNM/AJCC staging system (eighth edition), in the classification of patients with breast cancer seen at Hospital Ophir Loyola, a referral oncology hospital in the city of Belém, state of Pará, in 2018. Method: 176 medical records of patients undergoing treatment at Hospital Ophir Loyola, in 2018, were analyzed, which had information on the staging of the seventh edition and with immunohistochemical results. Result: 61.93% were between 40-60 years old, 46.2% were from the capital. Regarding the stage of diagnosis according to the 7th edition, 23 patients (13%) were in stage I, 66 cases (37.5%) in stage II, and the vast majority, totaling 77 cases (43.8%), in stage III. In addition, there were 03 cases (1.7%) in stage 0 (zero), and 07 cases (4%) in stage IV. There was a change in disease staging for 60.8% (107/176; 95%CI 53.4‒67.7) of the cases, 36.5% (39/107; 95%CI 28.0‒45.9) of these cases were upstaged, and in the others (63.5%, 68/107; 95%CI 54.1‒72.1), the change was to a lower prognostic category (down-staged). There was a significant increase in the proportion of cases staged in 2018 as IB and a significant reduction in cases staged by the most recent criterion such as IIB and IIIA (p<0.0001). Conclusion: the changes to new staging have shown to be more effective on the behavior of the tumor, helping in therapeutic decisions.

Sign in / Sign up

Export Citation Format

Share Document